Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

After a few years of stagnation, this stock is soaring.

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna, Inc. (NASDAQ:MRNA) traded at around $196 on October 7, up 4.81% on the day and 571.42% higher over twelve months. Nasdaq said the company will rejoin the Nasdaq-100 before the open on October ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.